The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Sertraline versus other antidepressive agents for depression
Open accessAbstract
BACKGROUND: Mirtazapine has a unique mechanism of antidepressive action and is one of the commonly used antidepressants in clinical practice. OBJECTIVES: The aim of the present review was to assess the evidence on the efficacy and acceptability of mirtazapine compared with other antidepressive agents in the acute-phase treatment of major depression in adults. SEARCH METHODS: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis review group's specialised register (CCDANCTR), which includes relevant randomised controlled trials from the following bibliographic databases: The Cochrane Library (all years to April 2011), EMBASE, (1980 to July 2011) MEDLINE (1950 to July 2011) and PsycINFO (1974 to July 2011). Reference lists of the reports of relevant studies were checked and experts in the field contacted. The review was not limited to English-language articles. SELECTION CRITERIA: Randomised controlled trials (RCTs) allocating participants with major depression to mirtazapine versus any other antidepressive agent. DATA COLLECTION AND ANALYSIS: Two authors independently checked eligibility and extracted data on an intention-to-treat basis. The primary outcome was response to treatment. The secondary outcomes included dropouts and individual adverse events.Meta-analyses were conducted using the random-effects model. MAIN RESULTS: A total of 29 RCTs (n = 4974), mostly following up the participants for six weeks in outpatient clinics and inadequately reporting the risk of bias, were included. In comparison with tricyclic antidepressants (10 trials, n = 1553) there was no robust evidence to detect a difference between mirtazapine and tricyclics in terms of response at two weeks (odds ratio (OR) 0.85, 95% confidence interval (CI) 0.64 to 1.13) or at the end of acute-phase treatment (at 6 to 12 weeks) (OR 0.89, 95% CI 0.72 to 1.10). In comparison with selective serotonin reuptake inhibitors (SSRIs) (12 trials, n = 2626) mirtazapine was significantly more effective at two weeks (OR 1.57, 95% CI 1.30 to 1.88) and at the end of acute-phase treatment (OR 1.19, 95% CI 1.01 to 1.39). Mirtazapine was significantly more effective than a serotonin-noradrenaline reuptake inhibitor (venlafaxine only, two trials, n = 415) at two weeks (OR 2.29, 95% CI 1.45 to 3.59) and at the end of acute-phase treatment (OR 1.53, 95% CI 1.03 to 2.25).In terms of dropouts, there was no robust evidence to detect a difference between mirtazapine and other antidepressants. Mirtazapine was more likely to cause weight gain or increased appetite and somnolence than SSRIs but less likely to cause nausea or vomiting and sexual dysfunction. AUTHORS' CONCLUSIONS: Some statistically significant and possibly clinically meaningful differences between mirtazapine and other antidepressive agents were found for the acute-phase treatment of major depression. Mirtazapine is likely to have a faster onset of action than SSRIs during the acute-phase treatment. Dropouts occur similarly in participants treated with mirtazapine and those treated with other antidepressants, although the adverse event profile of mirtazapine is unique.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–228 of 228
Lépine, J. P., Goger, J., Blashko, C., Probst, C., Moles, M.-F., Kosolowski, J., Scharfetter, B., & Lane, R. M. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015050-00003 · Cited by 19
Paslakis, G., Luppa, P. B., Gilles, M., Kopf, D., Weber-Hamann, B., Lederbogen, F., & Deuschle, M. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.11.015 · Cited by 19
Kang, E.-H., Lee, I.-S., Chung, S.-K., Lee, S.-Y., Kim, E., Hong, J.-P., Oh, K., Woo, J., Kim, S., Park, J. E., et al. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.06.021 · Cited by 18
The need for new and better antidepressants: reboxetine a new option
Dencker, S. J. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.02602.x · Cited by 17
Eker, S. S., Akkaya, C., Akgöz, S., Sarandöl, A., & Kırlı, S. (2005) · PubMed · Cited by 17
Milnacipran versus other anti-depressive agents for depression
Nakagawa, A., Watanabe, N., Omori, I. M., Cipriani, A., Barbui, C., McGuire, H., Churchill, R. C., Furukawa, T. A., & Ant, M.-A. O. N. G. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006529 · Cited by 16
Self-citationMirtazapine versus other anti-depressive agents for depression
Watanabe, N., Omori, I. M., Nakagawa, A., Cipriani, A., Barbui, C., McGuire, H., Churchill, R. C., Furukawa, T. A., & Ant, M.-A. O. N. G. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006528 · Cited by 15
Self-citationParoxetine versus other anti-depressive agents for depression
Cipriani, A., Furukawa, T. A., Veronese, A., Watanabe, N., Churchill, R. C., McGuire, H., & Barbui, C. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006531 · Cited by 15
Self-citationBaca, E., de Ch'avez, M., García-Toro, M., Perez-Arnau, F., & Porras-Chavarino, A. (2003) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00038-1 · Cited by 14
Venlafaxine versus other anti-depressive agents for depression
Cipriani, A., Signoretti, A., Furukawa, T. A., Churchill, R. C., Tomelleri, S., Omori, I. M., McGuire, H., & Barbui, C. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006530 · Cited by 13
Self-citationMoclobemide and sertraline in the treatment of depressive disorders: a comparative study.
Orsel Donbak, S., Mh, T., Ez, O. K., Demirergi, N., Akdemir, A., Şirin, A., & Ozbay, M. (1995) · PubMed · Cited by 12
Citalopram versus other anti-depressive agents for depression
Imperadore, G., Cipriani, A., Signoretti, A., Furukawa, T. A., Watanabe, N., Churchill, R. C., McGuire, H., Barbui, C., & Purgato, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534 · Cited by 12
Self-citationFluvoxamine versus other anti-depressive agents for depression (Protocol)
Omori, I. M., Watanabe, N., Cipriani, A., Barbui, C., McGuire, H., Churchill, R. C., & Furukawa, T. A. (2006) · Cited by 10
Self-citationFluvoxamine versus other anti-depressive agents for depression
Omori, I. M., Watanabe, N., Nakagawa, A., Cipriani, A., Barbui, C., McGuire, H., Churchill, R. C., Furukawa, T. A., & Ant, M.-A. O. N. G. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006114 · Cited by 7
Self-citationVersiani, M. (2000) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500050518082 · Cited by 6
Escitalopram versus other anti-depressive agents for depression
Cipriani, A., Pontarollo, F., Signoretti, A., Furukawa, T. A., Nakagawa, A., Churchill, R. C., McGuire, H., Barbui, C., & Ant, M.-A. O. N. G. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006532 · Cited by 5
Self-citationBuspiron and pindolol in augmentation therapy of treatment-resistant depression
Gönül, A. S., Oğuz, A., Yabanoğlu, İ., Aslan, S. S., & Turan, T. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)80131-x · Cited by 4
Mirtazapine versus amitriptyline in treatment of major depressive disorder
Turan, M., Aşkın, R., Telcioǧlu, M., & Çilli, A. S. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80159-5 · Cited by 4
Venlafaxine vs imipramine, sertraline in treating depression
Chen, Z. (2001) · Chinese Journal of New Drugs and Clinical Remedies · Cited by 4
Geddes, J. R., Butler, R., Hatcher, S., Cipriani, A., Price, J., Carney, S. M., & Korff, M. V. (2004) · PubMed · Cited by 4
Self-citationComparative study on mirtazapine and paroxetine in the treatment of depression
Hu, Y. N. (2006) · The Journal of Clinical Psychiatry · Cited by 3
Comparative study of mirtazapine and paroxetine in the treatment of depression
Lei, D. (2005) · Modern Medicine Health · Cited by 3
A study of mirtazapine and paroxetine in the treatment of depression
Mao-qiao, C. (2004) · Cited by 3
Guo, P. (2006) · Zhongguo yiyuan yongyao pingjia yu fenxi · Cited by 2
Efficacy of Mirtazapine and Sertraline in the Treatment of Depression with Anxiety Symptoms
Li, Z. (2004) · Zhongguo xinli weisheng zazhi · Cited by 2
Yu-zhong, S. (2003) · Chinese New Drugs Journal · Cited by 2
Clinical Efficacy and Compliance of Mirtazapine in the Treatment of Depression
Wenxin, T. (2004) · Zhongguo xinli weisheng zazhi · Cited by 2
Efficacy of mirtazapine vs clomipramine in severely depressed, hospitalized patients
Peyron, E. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)83105-1 · Cited by 1
Research works printed but not linked: 16
- Khoury A Aberg Wistedt A Stain Malmgren R Effect of sertraline and paroxetine treatment on depression scores and peripheral indices of serotonergic function in major depression 11th European College of Neuropsychopharmacology Congress. Paris, France. 31st October 4th November 1998 Utrecht ECNP 1998 · doi:10.1016/s0924-977x(98)80273-3
- Behan, 1995, 5-HT reuptake inhibitors in CFS, EOS Rivista di Immunologia ed Immunofarmacologia, 15, 66
- Fournier, 1997, A double-blind comparison of sertraline and imipramine in outpatients with major depression: Acute (8 weeks) and continuation (16 weeks) treatment, Human Psychopharmacology, 12, 203, 10.1002/(SICI)1099-1077(199705/06)12:3<203::AID-HUP849>3.0.CO;2-V · doi:10.1002/(sici)1099-1077(199705/06)12:3<203::aid-hup849>3.0.co;2-v
- Hegerl, 1997, Sertraline versus amitriptyline in hospitalized patients with major depression, Pharmacopsychiatry, 30, 175
- Kamijima, 1997, A double-blind, group comparison study of sertraline by hydrochloride vs amitriptyline hydrochloride, Japanese Journal of Neuropsychopharmacology, 19, 529
- Lee, 1994, Efficacy of sertraline in dysthymia, Neuropsychopharmacology, 10, 222S
- Murasaki, 1997, Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor for depression and depressive state-A double-blind study compared with imipramine hydrochloride, Japanese Journal of Meuropsychopharmacology, 19, 505
- Tsutsui, 1997, Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor in the treatment of depression and depressive state: a double-blind, group comparison study of sertraline hydrochloride vs trazodone hydrochloride, Shinkeiseishinyakuri, 19, 549
- Finkel S Richter E Double-blind comparison of sertraline and nortriptyline in late-life depression 8th ECNP (European College of Neuropsychopharmacology) Congress. Venice, Italy Utrecht ECNP 1995 · doi:10.1016/0924-977x(95)90482-s
- Gonul, 1999, Selective serotonin reuptake inhibitors: discontinuation rates due to side effects, European Neuropsychopharmacology, 9, 215, 10.1016/S0924-977X(99)80132-1 · doi:10.1016/s0924-977x(99)80132-1
- Latimer PR Ravindran AV Bernatchez JP Fournier JP Gojer JA Barratt K & Buttars J A six month comparison of toleration and efficacy of sertraline and fluoxetine treatment of major depression XXth Collegium Internationale Neuro psychopharmacologicum Melbourne, Australia 1996 · doi:10.1016/0924-977x(96)87876-x
- American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders (DSM-III)
- Guy, 1970, Manual for the ECDEU Assessment Battery.2
- National Institute for Clinical Excellence, 2004, Depression: management of depression in primary and secondary care
- World Health Organization, 1978, The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD-9)
- World Health Organization, 1982, The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10)
Cited by
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., et al. (2021) · Neurology International · doi:10.3390/neurolint13030038 · Cited by 440
Atkin-Smith, G. K., Tixeira, R., Paone, S., Mathivanan, S., Collins, C., Liem, M., Goodall, K. J., Ravichandran, K. S., Hulett, M. D., & Poon, I. K. H. (2015) · Nature Communications · doi:10.1038/ncomms8439 · Cited by 398
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
Taylor, D., Sparshatt, A., Varma, S., & Olofinjana, O. (2014) · BMJ · doi:10.1136/bmj.g1888 · Cited by 334
Metadata
- Authors
- Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2010-04-14
- Issue
- 12
- Pages
- CD006117-CD006117
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1904816587
- Cited by
- 299
- References
- 228
- FWCI
- 18.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.